Lamivudine News and Research

RSS
Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

Janssen presents EDURANT 96-week Phase 3 trial data at International AIDS Society Conference

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

ISENTRESS demonstrates comparable efficacy to efavirenz in treatment-naïve adult HIV-1 patients

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

Study shows possibility of women living with AIDS to breastfeed with lower risk

Study shows possibility of women living with AIDS to breastfeed with lower risk

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Merck's VICTRELIS phase III study results against HCV presented at EASL annual meeting

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Treatment for HBV infection with entecavir followed by lamivudine results in virologic rebound

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Sequential treatment with Entecavir and Lamivudine results in rebound of hepatitis B virus

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

HIV prevention, treatment highlighted at Conference on Retroviruses and Opportunistic Infections

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Pediatrician unveils latest findings of IMPAACT HIV/AIDS study during 2011 CROI

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Tibotec grants multiple non-exclusive licenses to generic manufacturers for rilpivirine hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

Matrix enters licensing agreement with Tibotec for generic Rilpivirine Hydrochloride

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

FDA provides tentative approval under PEPFAR for Matrix's Lamivudine and Zidovudine NDA

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Merck announces initial results from ISENTRESS Phase III study in HIV-1

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead submits Truvada/TMC278 single-tablet regimen NDA to FDA

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

Gilead to present data of two Phase III trials evaluating Viread efficacy for HBV infection at The Liver Meeting 2010

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

BARACLUDE sNDA receives FDA approval for treatment of CHB patients with decompensated liver disease

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment